BAK linked to ocular surface damage in animal studies

Article

Prostaglandin analogues preserved with benzalkonium chloride (BAK) can cause more extensive loss of goblet cells and a breakdown of cell-cell adhesions, which could increase the risk of ocular surface disease, according to findings from a pair of studies conducted in rabbits.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
Rethinking race as a risk factor for glaucoma

Rethinking race as a risk factor for glaucoma

M. Roy Wilson, MD, MS
April 9th 2025
Article

Social determinants of health challenge our existing expectations

A close-up of an elderly patient's face. They are administering eye drops. Image credit: ©photocrew – stock.adobe.com

Nicox SA shares research findings from NCX 470 Mont Blanc Phase 3 glaucoma trial

Jordana Joy
March 7th 2025
Article

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

The Voyager Direct Selective Laser Trabeculoplasty device. Image courtesy of Alcon.

Alcon launches Voyager direct selective laser trabeculoplasty device in the US

Sheryl Stevenson
February 21st 2025
Article

Voyager DSLT is already available in select markets in the EU and the UK, and reduces the specialised training required with manual selective laser trabeculoplasty

An illustration of two human figures. One has an illustration of a brain in their head, the other has a lot of scribble lines where the brain should be. ©melita – stock.adobe.com

Helping patients with glaucoma manage mental health

Lynda Charters; Leon Herndon Jr, MD
February 10th 2025
Article

The link between eye health and mental health may be deeper than previously believed

A collage which shows many of the Ophthalmology Times Europe covers from 2024.

See the best of our print edition with the 2024 cover story roundup

Hattie Hayes
December 23rd 2024
Article

Our top 10 print stories highlight the core content concepts we explored this year

A group of patients, including a diverse array of men, women and children, sit in a waiting room. Image credit: ©DC Studio – stock.adobe.com

Ethnic background has an impact on glaucoma outcomes

Lynda Charters; Reviewed by Atika Safitri, PhD
December 3rd 2024
Article

Gauging patient perceptions in an ethnically diverse UK cohort

© 2025 MJH Life Sciences

All rights reserved.